InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Sunday, 12/01/2019 8:45:32 PM

Sunday, December 01, 2019 8:45:32 PM

Post# of 67
News: $ESALY Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China

TOKYO, Dec 2, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of...

In case you are interested ESALY - Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China